Absci Corporation
ABSI
$-0.13
Change (1 day)
$6.72
Year High
$1.35
Year Low
Categories
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Revenue of Absci Corporation (ABSI)
Revenue in 2023 (TTM): $5.72 M
According to Absci Corporation's latest financial reports the company's current revenue (TTM) is $5.72 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Absci Corporation
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5.72 M | $-41,849,000 | $-95,457,000 | $-110,466,000 | $-110,566,000 |
| 2022 | $5.75 M | $-7,290,000 | $-91,356,000 | $-105,365,000 | $-104,904,000 |
| 2021 | $4.78 M | $-1,872,000 | $-99,773,000 | $-109,859,000 | $-100,960,000 |
| 2020 | $4.78 M | $-6,668,000 | $-12,588,000 | $-14,353,000 | $-14,569,000 |
| 2019 | $2.06 M | $-2,251,000 | $-5,825,000 | $-6,584,000 | $-6,801,000 |